Metraipolis › archive › dc_a0bb724fe109
Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41441327
- DOI
- 10.3390/pharmacy13060179
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T17:54:15.964Z
- SHA-256 of the archived text
a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087- Stable URL of this page
https://metraipolis.com/documento/dc_a0bb724fe109
How to cite
Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327 — Europe PMC (en), https://europepmc.org/article/MED/41441327 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a0bb724fe109 (Metraipolis archive dc_a0bb724fe109, sha256 a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087)
BibTeX
@misc{dca0bb724fe109,
title = {Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41441327},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a0bb724fe109; sha256 a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41441327. Agents can read the archived copy with the MCP tool read_document.